Evonik Invests €80 Million in Slovakia
Evonik is expanding its biotechnological production capacities at the Fermas site in Slovenská Ľupča with an investment of around €80 million. The measure is aimed at expanding downstream fermentation for the production of active ingredients for pharmaceutical customers and will create around 50 new jobs.
The focus is on the expansion of modern downstream fermentation technology, which is intended to strengthen the customer synthesis business as the Group's CDMO (Contract Development and Manufacturing Organization). The expansion will create around 50 new jobs at the site.
"With the increasing demand for complex active pharmaceutical ingredients, the expansion of our biotechnological production capacities will enable a reliable, scalable and sustainable supply for our customers," said Guido Skudlarek, Head of the Health Care Business Line at Evonik.
This is already the second significant investment at Fermas in just a few years: construction of the world's first rhamnolipid plant was initiated there in 2022. Since 2024, Evonik claims to have been the first company in the world to produce rhamnolipid-based biosurfactants on an industrial scale. The site has developed into a center for biotechnological production on an industrial scale and is continuously expanding its capacities in fermentation and downstream processing.
"I am proud that our Slovenská Ľupča site is helping leading life science companies worldwide to tackle some of the most pressing challenges of our time," said Miroslav Havlik, Managing Director of Evonik Fermas. "Our investment not only supports a more sustainable future for global healthcare solutions, but also strengthens our region."
